Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
EG.8ORF1abWon-ORF1abTGCATTAACATTGGCCGTGA20451555815539R-21175.8South Korea
FL.32ORF1abWon-ORF1abTGCATTAACATTGGCCGTGA20451555815539R-21175.8South Korea
FL.26.1ORF1abWon-ORF1abTGCATTAACATTGGCCGTGA20451555815539R-21175.8South Korea
EG.6ORF1abWon-ORF1abTGCATTAACATTGGCCGTGA20451555815539R-21175.8South Korea
FK.1.3.1ORF1abWon-ORF1abTGCATTAACATTGGCCGTGA20451555815539R-21175.8South Korea
FK.1.2.2ORF1abWon-ORF1abTGCATTAACATTGGCCGTGA20451555815539R-21175.8South Korea
FK.1ORF1abWon-ORF1abTGCATTAACATTGGCCGTGA20451555815539R-21175.8South Korea
CH.1.1.18ORF1abWon-ORF1abTGCATTAACATTGGCCGTGA20451555815539R-21175.8South Korea
XBB.1.5.9ORF1abWon-ORF1abTGCATTAACATTGGCCGTGA20451555815539R-21175.8South Korea
BF.7ORF1abWon-ORF1abTGCATTAACATTGGCCGTGA20451555815539R-21175.8South Korea
BA.5.1.5ORF1abWon-ORF1abTGCATTAACATTGGCCGTGA20451555815539R-21175.8South Korea
BQ.1ORF1abWon-ORF1abTGCATTAACATTGGCCGTGA20451555815539R-21175.8South Korea
BA.5.2.20ORF1abWon-ORF1abTGCATTAACATTGGCCGTGA20451555815539R-21175.8South Korea
LZ.1.1ORF1abWon-ORF1abTGCATTAACATTGGCCGTGA20451555815539R-21175.8South Korea
KP.3.1.5ORF1abWon-ORF1abTGCATTAACATTGGCCGTGA20451555815539R-21175.8South Korea
KW.1.1.1ORF1abWon-ORF1abTGCATTAACATTGGCCGTGA20451555815539R-21175.8South Korea
KU.2ORF1abWon-ORF1abTGCATTAACATTGGCCGTGA20451555815539R-21175.8South Korea
JN.1.4.6ORF1abWon-ORF1abTGCATTAACATTGGCCGTGA20451555815539R-21175.8South Korea
KP.2.5ORF1abWon-ORF1abTGCATTAACATTGGCCGTGA20451555815539R-21175.8South Korea
LP.2ORF1abWon-ORF1abTGCATTAACATTGGCCGTGA20451555815539R-21175.8South Korea
AY.105 (Delta)NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-21174.1US
XBWNUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-21174.1US
BQ.1.1.78NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-21174.1US
B.1.359NNIH-TH_NCCCCACTGCGTTCTCCATT1957.892837628358R-21165.1Thailand
AY.62 (Delta)NNIH-TH_NCCCCACTGCGTTCTCCATT1957.892837628358R-21165.1Thailand
XCRSWuhanCoV-spk1TTGGCAAAATTCAAGACTCACTTT2433.332435424377F-21139.8Japan
B.1.541NCorman-NGAGGAACGAGAAGAGGCTTG20552883328814R-21137.4Germany
B.1.1.423NCorman-NGAGGAACGAGAAGAGGCTTG20552883328814R-21137.4Germany
R.1NCorman-NGAGGAACGAGAAGAGGCTTG20552883328814R-21137.4Germany
B.1.416.1NCorman-NGAGGAACGAGAAGAGGCTTG20552883328814R-21137.4Germany
B.1.629NCorman-NGAGGAACGAGAAGAGGCTTG20552883328814R-21137.4Germany
B.1.265NCorman-NGAGGAACGAGAAGAGGCTTG20552883328814R-21137.4Germany
B.1.1.512NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.349NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.265NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.401NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.362NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.1.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GK.2.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FW.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HN.3.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.1.1.17NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BS.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CM.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.75.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CA.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.453NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.637.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.79NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BG.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used